. Author manuscript; available in PMC: 2020 Jul 22.

Published in final edited form as: JACC Cardiovasc Interv. 2019 Jul 22;12(14):1328–1338. doi: 10.1016/j.jcin.2019.06.013

Table 3.

Characterization of currently available TAVR mortality risk scores.

Score(year)	Population	Primary outcome	AUC
FRANCE-2 (2014)	Total: n=3,833 Derivation cohort: n=2,552 Validation cohort: n=1,281	30-day mortality	0.59
TARIS (2014)	Total: n=1,178 Derivation cohort: n=845 Validation cohort: n=333	30-day mortality	0.69
OBSERVANT (2014)	Total: n=1,878 Derivation cohort: n=1,256 Validation cohort: n=622	30-day mortality	0.71
TAVI₂ (2015)	Total: n=511 Derivation cohort: n=511 Validation cohort: n=100^†	1-year mortality	0.72
CoreValve US (2016)	Total: n=3,687 Derivation cohort: n=2,482 Validation cohort: n=1,205	30-day and 1-year mortality	0.75 and 0.79, respectively
STS/ACC TVT (2016)	Total: n=20,540 Derivation cohort: n=13,672 Validation cohort: n=6,868	In-hospital mortality	0.66
UK TAVI (2017)	Total: n= 6,339 Derivation cohort: n=6,339 Validation cohort: n=2,969^†	30-day mortality	0.66
CAPRI (2019)	Total: n= 1,736 Derivation cohort: n=1,425 Validation cohort: n=311	1 -year mortality	0.68
NIS TAVR (2019)^*	Total: n= 10,891 Derivation cohort: n=7,624 Validation cohort: n=3,667	In-hospital mortality	0.92

^†

Validation sample was obtained from the derivation cohort.

Best model obtained in our study.